Associated tags: Disease, RNA, Biotechnology, Health, Renegade, Therapy, Pharmaceutical, Genetics, Research, Vaccine, Cell, LNP, Science
Locations: GERMANY, EUROPE, AUSTRALIA, PENNSYLVANIA, SWITZERLAND, ASIA PACIFIC, CA, SAN FRANCISCO, UNITED STATES, NORTH AMERICA, MASSACHUSETTS, MARYLAND, BALTIMORE
Biotechnology,
Other Health,
Health,
General Health,
Pharmaceutical,
Oncology,
Health Technology,
Other Science,
Research,
Genetics,
Science,
Stanford University,
Hospital,
Nobel Prize,
RNA,
GlycoRNA,
Cell,
Boston,
Humanities,
Stanford School,
Renegade,
Patient,
Assistant,
Therapy ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem.
Key Points:
- ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem.
- GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade.
- “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade.
- Glycobiology-based RNA medicines represent a new frontier, and it is rewarding to see the possibilities of ReNAgade developing these for clinical use.”
Health,
Stem Cells,
Genetics,
Health Technology,
Pharmaceutical,
Biotechnology,
Abstract (summary),
RNA,
Cell,
Engineering,
Renegade,
Gene,
Society,
Small RNA,
Stem cell,
RT,
Annual general meeting,
Therapy,
Vaccine ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced an oral and poster presentation highlighting preclinical data supporting its comprehensive RNA technology platform at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11, 2024, in Baltimore, Maryland.
Key Points:
- ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced an oral and poster presentation highlighting preclinical data supporting its comprehensive RNA technology platform at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11, 2024, in Baltimore, Maryland.
- Improved retron-mediated target insertion through a combination of retron reverse transcriptase (RT) engineering, non-coding RNA (ncRNA) minimization, chemical modification, and homology-dependent repair manipulation.
- Combination of retron system optimization and ncRNA engineering led to 2-fold higher 305 base pair insertion and ~40% editing efficiency in hematopoietic stem cells.
- ASGCT Annual Meeting Presentation Details:
Retrieved on:
Tuesday, February 27, 2024
Biotechnology,
Health,
Genetics,
Pharmaceutical,
Oncology,
Bangladesh Technical Education Board,
Takeda Pharmaceutical Company,
MPM,
Schering-Plough,
Science Publishing Group,
Hoechst AG,
Research and development,
NIH,
Moderna,
PureTech Health,
Drug development,
Bristol Myers Squibb,
Doctor of Philosophy,
Renegade,
University,
Partner,
RNA,
Therapy,
Patient,
Protein,
Takeda Oncology,
Development,
Immune system,
Pharmaceutical industry ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.
Key Points:
- ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.
- “Joe is a pioneering scientist and drug development expert who brings to ReNAgade more than four decades of experience in oncology and immunology,” said Amit D. Munshi, Chief Executive Officer of ReNAgade.
- Before joining PureTech, he oversaw all aspects of research and development for Moderna Therapeutics as President of Research & Development and Chief Scientific Officer.
- Previously, he was Chief Scientific Officer at Millennium Pharmaceuticals and Global Head of Oncology Research at Takeda Pharmaceutical Company.
Retrieved on:
Thursday, February 22, 2024
Health,
Technology,
Stem Cells,
Nanotechnology,
Genetics,
Pharmaceutical,
Biotechnology,
Renegade,
RNA,
Therapy,
Conference,
Webcast,
Evercore,
News ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Amit D. Munshi, Chief Executive Officer, will virtually present at the Evercore ISI 2024 Emerging Biotech Conference on Thursday, February 29, 2024, at 9:35 a.m.
Key Points:
- ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Amit D. Munshi, Chief Executive Officer, will virtually present at the Evercore ISI 2024 Emerging Biotech Conference on Thursday, February 29, 2024, at 9:35 a.m.
- ET.
- A webcast of the event will be available in the "News" section of the Company's website at https://renagadetx.com/news/ .
- A replay of the webcast will be archived on the Company's website for 90 days following the presentation date.
Retrieved on:
Thursday, January 4, 2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Amit D. Munshi, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 8:30 a.m. PT in San Francisco, CA.
Key Points:
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Amit D. Munshi, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 8:30 a.m. PT in San Francisco, CA.
Retrieved on:
Tuesday, December 5, 2023
Biotechnology,
Pharmaceutical,
Genetics,
Health,
CSL,
Kellogg School,
Therapy,
Central Florida,
Pharmacy,
University,
Renegade,
Management,
RNA,
Growth,
Harvard Business School,
Knowledge,
Kellogg School of Management,
Drug development,
Psychology ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced the appointment of Paul Perreault to its Board of Directors, effective December 5, 2023.
Key Points:
- ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced the appointment of Paul Perreault to its Board of Directors, effective December 5, 2023.
- Mr. Perreault most recently served as Chief Executive Officer of CSL and brings over 40 years of leadership experience across the biotechnology industry.
- “Paul is a distinguished industry executive recognized for his extensive track record in drug development and was integral to the growth of CSL to become an international leader in the field.
- “We are pleased to welcome Paul to the ReNAgade team and look forward to his contributions.”
“I am thrilled to join ReNAgade at this exciting time for the company,” said Mr. Perreault.
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Biotechnology,
Stem cell,
RNA,
Renegade,
LNP,
Liver,
Conference,
Cell,
CD34,
NK,
Messenger,
MPP,
Therapy,
NHP,
HSPC,
Vaccine ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced it will present preclinical data demonstrating novel and proprietary lipid nanoparticle (LNP)-based delivery of mRNA to extra-hepatic tissue in a plenary session at the 11th International mRNA Health Conference, being held October 31 to November 2, 2023 in Berlin, Germany.
Key Points:
- ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced it will present preclinical data demonstrating novel and proprietary lipid nanoparticle (LNP)-based delivery of mRNA to extra-hepatic tissue in a plenary session at the 11th International mRNA Health Conference, being held October 31 to November 2, 2023 in Berlin, Germany.
- “Delivery to extra-hepatic tissue is foundational to our approach, and these data help validate how our diverse LNP library can complement our multi-modal RNA platform to create a robust therapeutic pipeline.
- Proprietary LNP delivery to natural killer (NK) cells was also identified via a high-throughput, functional barcoding screening in NHP models.
- Taken together, potent delivery of ReNAgade’s proprietary LNPs was observed in natural killer cells and several subsets of HSCs over multiple animal models (including NHP and humanized murine models), demonstrating robust LNP delivery of mRNA cargo to extra-hepatic tissue.
Retrieved on:
Thursday, September 21, 2023
Health,
Genetics,
Research,
Pharmaceutical,
Science,
Biotechnology,
Renegade,
LNP,
Therapy,
RNA,
Disease,
Vaccine ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that it has been named as one of the Endpoints 11 companies of 2023 , awarded by Endpoints News editor John Carroll to the most promising private biotechnology companies in the industry.
Key Points:
- ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that it has been named as one of the Endpoints 11 companies of 2023 , awarded by Endpoints News editor John Carroll to the most promising private biotechnology companies in the industry.
- “To be included as one of the Endpoints 11 top private biotech companies is not only a great honor for our young company, but also recognition from the industry of what we’ve already accomplished in the past 18 months toward our aim of overcoming the current limitations of RNA medicines,” said Amit D. Munshi, Chief Executive Officer of ReNAgade.
- “The Company has continued to grow since our $300 million Series A financing round, building on our world-class, multidisciplinary team that is dedicated to innovating delivery technology and bringing an array of genomic medicine tools under one roof.
- We look forward to expanding the reach of RNA medicine beyond what was previously thought possible, beginning with important preclinical extra-hepatic data which we expect to present soon.”
ReNAgade has built a broad portfolio of proprietary RNA delivery systems, including novel lipid nanoparticles (LNPs), together with comprehensive genomic coding, editing and insertion technologies to precisely correct disease on an unprecedented scale and profoundly expand the array of addressable diseases.
Retrieved on:
Tuesday, September 12, 2023
Health,
Genetics,
Research,
Pharmaceutical,
Science,
Biotechnology,
Tissue,
Treasury,
Amgen,
University,
Mirati Therapeutics,
Renegade,
Anderson School,
Cell,
RNA,
UCLA Anderson School of Management,
Acquisition,
Arizona State University,
CFO,
Growth,
Therapy,
Accounting,
Pfizer,
Management ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced the appointment of Laurie Stelzer as Chief Financial Officer.
Key Points:
- ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced the appointment of Laurie Stelzer as Chief Financial Officer.
- Ms. Stelzer most recently served as Chief Financial Officer of Mirati Therapeutics and brings over 25 years of experience to further strengthen ReNAgade’s leadership team.
- “Laurie is an accomplished leader with extensive experience across the pharmaceutical and biotech industries, whose work has spanned corporate finance and strategy, business development, and helping to build key capabilities necessary to create long-term value for stakeholders,” said Amit D. Munshi, Chief Executive Officer of ReNAgade.
- “Having worked with Laurie for over 20 years, I am very excited to welcome her to the ReNAgade leadership team as our first Chief Financial Officer as we continue to advance our science and growth of the company.”
“In advancing its industry leading platform, ReNAgade is poised to bring RNA medicines to previously inaccessible tissues and cells in the body,” said Ms. Stelzer.
Biotechnology,
Genetics,
Health,
Boston Consulting Group,
Tissue,
Therapy,
Senior,
Arena Pharmaceuticals,
Renegade,
Bristol Myers Squibb,
Cell,
RNA,
Partner,
Merck,
Johnson & Johnson,
Shirin David,
LNP,
MPM,
Disease,
J. P. Morgan,
Vaccine,
Moderna,
Alnylam Pharmaceuticals ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines to correct disease, today announced a $300 million Series A financing round led by MPM BioImpact and F2 Ventures.
Key Points:
- ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines to correct disease, today announced a $300 million Series A financing round led by MPM BioImpact and F2 Ventures.
- ReNAgade aims to address major limitations in RNA therapeutics by enabling the delivery of RNA medicines to previously inaccessible tissues and cells in the body, substantially expanding the potential addressable disease market.
- The Company has an established Joint Venture with Orna Therapeutics Inc., combining ReNAgade’s delivery platform with Orna’s circular RNA technology.
- “By innovating on delivery technology and bringing an array of genomic medicine tools under one roof, ReNAgade is poised to deliver RNA to organs and tissues not previously accessible.
